life scienc tool diagnost compani updat
multipl metric analyz demand environ clinic lab test includ googl
search interest total/new prescript rx volum googl tracker util
real-tim search data forecast access volum
labcorp lh impli organ volum growth lh
respect trend well new volum estim
org report lh org report view analysi
fulli reflect dynam result reduct physician
offic visit cancel elect procedur custom close sever curtail
oper adopt work home polici pressur core test volum
meanwhil iqvia data mix qtd adj prescript volum rise
averag vs physician offic visit deceler
trail basi vs consist aforement covid disrupt
print view latest result googl tracker less relev
reflect retract guid follow
volum declin inclus test last two week covid
prevent measur light dynam expect continu
lower ep estim predic revenue
growth vs prior ebitda margin contract bp despit new cost-
cut initi includ reduct employe compens suspens
match supplement defer compens plan furlough reduc overtim
hire freez meanwhil ep also move
revenu growth vs prior easi volum comp delay pama-rel
price cut well bp margin expans regain oper leverag
continu execut cost save initi tp move
lower outer year view signific focu guidanc updat
test landscap core volum dynam new health plan relationship dtc channel
pln potenti risk includ regulatori reimburs deal integr
lh print similarli view latest result googl tracker also
less relev reflect fall core volum end
continu throughout meanwhil though view cro revenue essenti in-
line like abnorm cancel clinic trial prioriti remain intact lt view
near term clinic trial delay pressur result across covanc catch-
longer term cro download lower ep estim
predic drop revenue includ lcd
volum rev/accn cdd well bp ebitda margin
contract meanwhil ep move predic
revenue growth easi comp delay pama price cut lcd well
bp margin expans tp move lower outer year view
focu call guidanc updat test landscap core
cancel risk includ integr headwind reimburs pressur
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
test capac continu run
test per day increas test per day march expand
capac larg due addit test base nr platform
two lab began april well expand capac laboratori
develop test meanwhil lh like also increas capac vs prior test
per day march albeit unquantifi to-dat acla member includ lh
among other conduct approxim million test includ april
vs april april await updat capac
expans near term importantli test capac expand laboratori
abl reduc test backlog dgx anticip turnaround time
patient priorit program less one day averag test
achiev turnaround time less two day averag repres
meaning improv two week ago disclos averag
turnaround time day test take day
highlight pama relief price visibl part recent pass
care act pama cut expect delay one year
posit commerci lab includ lh moreov care act
also delay implement reduct cap one year
next round data collect remind pama design bring
medicar price par commerci market howev determin proper rate
collect price data total laboratori test market
includ low-cost provid like lh inevit led oner cut
appropri therefor past year lab industri fought adjust
data collect mechan illustr accur price landscap
recent delay may provid addit time resolv aforement concern note
previous estim headwind lh respect
formerli expect pama price cut
march retract guidanc note januari februari result
consist expect provid earn call core volum declin
march even greater headwind last two week march experienc
declin volum inclus test ramp social distanc
measur result signific reduct physician offic visit cancel
elect medic procedur custom close sever curtail oper
adopt work home shelter-in-plac polici among dynam
volum pressur disappoint anticip upcom volatil sever
durat pandem still unknown provid guidanc around potenti
financi impact albeit like detail provid call report april
base preliminari analysi extrapol full month impact vs dgx
disclos declin last two week march estim core volum declin could
repres ep headwind
increment cost-cut measur initi off-set covid pressur
april announc implement increment action address cost structur
light depress test volum due dynam includ cost-cut
effort expect temporarili reduc employe compens next week
includ reduc ceo pay board director forgo cash compens
period cut pay exempt employe depend level
moreov suspend compani match supplement defer
compens plan end year compani also approv furlough
employe diminish work employe dgx workforc
furlough to-dat step taken includ reduc hour non-exempt
employe reduc overtim freez virtual hire promot dismiss
temporari contract worker
recent invest genet
genet market
acknowledg profit import consider establish commerci lab
rel newer start-up result inher slower growth profil rel competitor
order support new offer sit payer well consult
physician clinic specialist prior launch advanc test panel blueprint
genet view compani bioinformat platform abl better support
turnaround time enabl compet effect moreov
acquir anyth across liquid biopsi space point recent invest appear
promis albeit date set yet clinic work read-out
remind acquir blueprint genet all-cash transact undisclos
amount januari financi disclosur transact limit estim
blueprint genet gener million revenu grow y/i albeit
like unprofit today meanwhil disclos size invest
relat detail relat liquid biopsi invest deal align
dgx strategi acceler growth across gene-bas esoter portfolio incl
advanc diagnost test servic revenu albeit drive near term dilut
unlik lh provid substanti updat recent relat
guidanc await detail earn report april
recent updat earli march lh note believ guidanc rang would
suffici cover impact albeit push pull exampl lh
note impact extend chines new year holiday central lab slowdown
clinic trial enrol europ howev time lh re-affirmed guidanc
yet experienc signific impact diagnost test us dynam view
clearli chang recent week note disclos declin total
volum last two week march also consist recent expert check see
expert call view lh like provid updat guidanc like
lower withdraw like expect light evolv dynam
said also view lh earn inher resili rel given diversifi
revenu stream clinic trial prioriti seem remain intact posit dynam
caught ia outperform syneo health outperform
discuss dynam implic cro industri
sign irregular level cancel coincid pandem sponsor
increasingli delay patient enrol new studi start consist data
track industri constitu clinicaltri gov analysi said clear
larg pharma/biopharma custom want continu move clinic trial work forward
encourag dynam view underappreci moreov proactiv
convert site activ remot monitor virtual trial possibl order
maintain integr regulatori complianc on-going studi still covid disrupt
inevit albeit temporarili slow backlog convers primarili like
depend durat view like gradual catch-up thereon net/net remain
posit bias cro sector emphas sustain prioriti
custom disrupt creat time issu
run test per day increas test per day
march expand capac due part addit test base holog
nr platform two lab began april well expand capac
laboratori develop test meanwhil lh like also increas capac vs prior
test per day march albeit unquantifi to-dat acla member includ
lh arup opko health biorefer mayo clinic exact scienc sonic
healthcar conduct approxim million test includ april vs
april april await updat capac expans near term
compani also explor addit option serolog test
test capac expand laboratori like abl significantli reduc
test backlog exampl dgx anticip turnaround time test patient
priorit program less one day averag test achiev
turnaround time less two day averag repres signific meaning
improv two week ago disclos averag turnaround time
day test take day
figur number test complet per day acla member
diagnost sonic healthcar exact scienc
laboratori volum googl search tracker util real-tim web search data identifi
proxi volum trend labcorp america current
quarter rational behind analysi mani patient util internet get
blood work done find relev test locat patient servic center hour schedul
appoint and/or learn specif test order physician track
search real-tim basi via googl trend enabl us get sens
volum specif labcorp quest may progress given period admittedli
analysi complic acquisit variabl taint regress analysi
note histor correl stronger quest labcorp
key caveat recent quarter view dynam may fulli
incorpor analysi search trend may inflat sever factor peopl
proactiv seek potenti test servic search updat viru broadli
cancel and/or defer appoint due social distanc protocol local mandat
figur histor report organ volum growth chart
labcorp america analysi project volum growth vs
analyz five year histor quarterli volum growth real-tim googl search interest
labcorp march project unadjust organ volum increas
importantli tracker remark high give us higher
degre confid regression-project adjust organ volum forecast
result ad averag quarterli delta last eight quarter
compar quarterli organ volum estim model growth
includ acquisit admittedli note key caveat googl tracker
index methodolog make regress analysi rel organ growth rate inher
difficult moreov discuss previous dynam may fulli
embed googl tracker analysi
figur lh googl tracker unadjust volum project repres acceler
quest diagnost analysi project org volum growth vs
use five year histor volum real-tim googl search interest quest lab
solsta march ameripath may march
covari project adjust volum increas accord
regress analysi result ad averag quarterli delta eight quarter
analysi quest exhibit rel high correl result
analysi project organ volum growth well estim view
googl tracker fulli reflect coronavirus-rel dynam discuss previous
report declin volum includ test last two
week march admittedli note key caveat googl tracker
index methodolog make regress analysi rel organ growth rate inher
difficult also note impact acquisit within past year may also fulli
reflect result estim contribut volum acquisit
figur googl tracker unadjust volum project vs
method disclosur
premis analysi reli idea portion health care util reflect
on-line activ patient mani first action taken upon ill need medic
attent util internet resourc address health concern track on-line
activ glean insight healthcar util occur acknowledg
track web search proxi laboratori volum limit assum
laboratori test associ web search conduct googl probabl
case major requisit search trend also influenc non-pati relat
activ investor media search activ complic matter
nonetheless believ grow use internet resourc healthcar googl
domin market share allow reason proxi caution investor read
much absolut volum growth project emphas direct implic
volum predict
prescript volum physician offic visit
figur present iqvia data analyz year year volum growth us
prescript note prescript volum rose march follow growth
februari growth januari improv growth
like benefit stock dynam relat figur break share
total prescript volum growth month came new prescript versu refil
note healthier mix new prescript data rel refil prescript
often correspond increment lab test physician visit all-import driver
laboratori volum specif new refil prescript grew
march averag respect
addit accord iqvia data admittedli identifi inconsist
sever restat monthli physician visit fell march albeit follow
fall visit februari roll averag total physician visit fell howev
would highlight histor physician offic visit trend iqvia somewhat
choppi inconsist clinic laboratori result
figur monthli total prescript volum refil rx new rx
figur monthli physician visit growth per iqvia
part recent pass care act pama cut expect
delay one year posit commerci lab includ lh moreov
care act also delay implement reduct cap one year
next round data collect encourag recent
develop provid visibl price reduct note previous
estim headwind lh respect formerli
expect roughli pama price cut
remind follow passag lab act late-decemb center
medicar medicaid publish press releas acknowledg delay data
report clinic lab fee schedul clf clinic diagnost laboratori test
cdlt one year data expect collect januari
march consist prior disclosur recent pass lab act also direct
medpac review methodolog previous implement collect prior payor
rate passag lab act subsequ press releas follow
introduct bipartisan legisl hous repres senat
mid- importantli clinic laboratori lobbi type
legisl constitu broadli view
fundament flaw obscur true price level across laboratori market
also encourag lab act potenti offer legisl pathway pama reform
pama data collect process
also highlight august american clinic laboratori associ acla
appeal us court appeal overturn prior judg decis throw
lawsuit claim implement data collect methodolog would result
inaccur result remind septemb district court district
columbia dismiss lawsuit base jurisdict issu albeit still acknowledg
pama timelineapril pamaseptemb preliminari clf rate announcedseptemb seriou concern propos ratesnovemb final clf rate announceddecemb acla file lawsuit claim implement data collect methodolog would result inaccur resultsjanuari clf implementedapril file repli brief support summari judgementseptemb dismiss case state acla jurisdict albeit acknowledg merit caseoctob appeal caseapril part appeal process parti conduct oral argument front appel judgejun bill improv data report pama introduc hous repres would delay next round report one yearaugust win appeal relat jurisdict issueoctob file motion summari judgementnovemb file opposit acla motion summari judgement along cross motion summari judgementdecemb bill improv data report pama lab act introduc senat senat burr browndecemb file repli support motion summari judgement opposit hh cross-mot summari judgement proj januari file repli support cross-mot summari data report period charl martineau pm univers toronto
view recent advanc pama reform front encourag still
conserv emb medicar price cut also view recent
develop provid visibl price reduct expect
price reduct accord analysi util clf expect test
rate reduc aggreg vs reduct cap moreov
go forward magnitud dollar impact like less contribut
note care act delay next round pama cut one year
said manag view increas awar pama drive increment attract
home focus laboratori meaning medicar exposur file bankruptci februari
provid indic potenti impact pama smaller player
regardless without pama relief lh view dynam drive industri
refer pama design bring medicar price part commerci market
counterpart howev determin proper rate collect price data
two largest nation lab labcorp quest diagnost repres
total laboratori test market moreov given two lab typic
consid lost-cost provid price smaller region player laboratori industri
argu inaccur calcul commerci rate lead far oner cut
appropri
 remain key compon growth strategi lead nation laboratori includ
quest diagnost labcorp continu view pama newli non-exclus
manag care contract potenti relat dynam spur greater market
consolid heighten reimburs cut flat due
covid/car act greater in-network access lh
nurs home focus laboratori meaning medicar exposur file bankruptci
februari provid indic potenti impact small player
howev key investor question past year pertain seen
greater number deal and/or higher acquisit contribut nation clinic
lab comment deal seemingli take long time complet due sheer
amount peopl involv transact intern structur prioriti
target moreov lh note uncertainti relat pama also like slow
convers view recent visibl spur deal flow refer
discuss acquir cape cod hospit outreach lab five year
abl final complet transact said lh note
pipelin robust head expect see increment stronger
deal flow/complet rel experi
 remain key compon dgx growth strategi deal close sinc
expect add least bp top-line growth annual go forward albeit
rate phase-in reduct capexpect aggreg phase growth headwindlh ex charl martineau pm univers toronto april
acknowledg transact contribut fairli light estimate bp notabl
acquir two region laboratori includ boyc bynum close
boston clinic laboratori compar activ year
region lab us lab servic oxford immunotec specialti region lab
marin gener hospit hospit outreach addit also
repurchas share year million/year averag pay dividend rais
announc typic announc januari payment date
recent acquir blueprint genet all-cash equiti transact
undisclos amount ad faster-grow platform specialti genet test portfolio
focus gene variant interpret report recent acquisit align
dgx strategi acceler growth across gene-bas esoter portfolio incl
test servic revenu wherebi blueprint
bioinformat clinic interpret platform leverag machin learn ai fill
key gap nation lab current servic offer importantli deal also support
collabor pharmaceut vitro diagnost includ solut joint
ventur iqvia hold sign juli remind creat world
second largest central laboratori note estim blueprint genet gener
million revenu grow y/i albeit like unprofit today
importantli attempt diversifi portfolio previous howev seven year ago
decid refocu core compet across diagnost inform servic market
therebi divest medic devic busi increas focu
expect see acquir like build new diversifi leg busi differ
lh covanc unit said see opportun expand capabl
core diagnost market expand beyond tradit laboratori servic also includ
medic checkup servic life insur compani provid employ well
program potenti work payor longer term relat risk pool
figur spent billion capit deploy
 also key piec lh longer term strategi pipelin focu across core
segment clinic diagnost cro term lcd segment lh favor small hospit
lab deal accret first year note pipelin like compris
smaller strateg tuck-in acquisit see mani larg deal million
market
cro perspect lh look bolster geograph footprint apac well
add capabl key market segment dynam also diversifi lh revenu
base expand area less tie core us clinic laboratori busi associ
reimburs risk remind april lh announc acquir preclin
research servic busi envigo see ink envigo deal bolster cro pursuant
deal term lh sell covanc research product envigo estimate sale million
result million net impli cash consider net divestitur estim
deal add million annual revenu accret ep year one
relat return capit sharehold lh discuss implement
potenti dividend annual board director continu view better util
cash via intern invest balanc util share repurchas
million/year averag said lh note potenti upsid opportun
dividend includ access new sharehold incom focus potenti provid
investor relief plan anoth large-scal acquisit covanc provid
sens capit return sharehold
figur lh spent billion capit deploy
note withdrew previous disclos guidanc march
labcorp revenu revenu revenu tax cash diagnost tax cash epsgreat guidanc contributiongreat return return return charl martineau pm univers toronto april
figur lh payor exposur pre cdd
note payor includ physician hospit occup test servic non-u clinic diagnost oper nutrit chemistri food safeti
oper beacon lb
labcorp america
life scienc tool diagnost
lh print similarli view latest result googl tracker also
somewhat less relev reflect fall core volum end march
continu throughout meanwhil though view cro revenu
essenti in-lin like abnorm cancel clinic trial prioriti
remain intact longer term view near term clinic trial delay pressur result across
covanc catch-up longer term see cro download
lower ep estim predic drop
revenu includ lcd volum rev/accn cdd
well bp ebitda margin contract meanwhil ep move
predic revenu growth easi comp delay
pama-rel price cut core lab busi well bp margin
expans tp move lower outer year view focu
call guidanc updat test landscap core volum
cancel risk includ integr headwind reimburs pressur
valuat metric
number share
 close
labcorp america lh
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
labcorp provid diagnost test inform servic clinic
better fundament perform sentiment could drive upsid
target price blue sky scenario lh
weaker fundament perform sentiment could lead downsid
versu target price grey sky scenario lh
 close
life scienc tool diagnost
print view latest result googl tracker less relev
reflect dynam note retract guidanc
march follow volum declin inclus test last two
week march ramp covid prevent measur light aforement
dynam expect continu lower
ep estim predic revenu growth vs prior
ebitda margin contract bp despit newli launch cost-cut
initi includ reduct employe compens suspens match
supplement defer compens plan furlough reduc overtim hire
freez meanwhil ep also move
revenu growth vs prior easi volum comp delay pama-rel
price cut well bp margin expans regain oper leverag
continu execut cost save initi tp move
lower outer year view signific focu guidanc updat
test landscap core volum dynam new health plan relationship dtc channel
pln potenti risk includ regulatori reimburs deal integr
valuat metric
number share
 close
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
provid diagnost test informatin servic
better fundament perform could come faster organ
growth gain in-network statu sentiment could drive
upsid target price blue sky scenario
weaker fundament perform sentiment could lead downsid
versu target price grey sky scenario
 close
compani mention price
labcorp america lh outperform tp
erin wilson wright certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view
express report
